MARATTO

article · Applied Organometallic Chemistry

Synthesis, spectral analysis, XRD, molecular docking simulation of dithranol and glycine mixed ligand complexes and their potential role in suppressing breast cancer cells via down‐regulating the expression of protein metalloproteinase‐9

202426 citationsOpen accessZagazig University

In plain language

Five novel metal complexes incorporating dithranol and glycine were synthesised using nickel, zinc, zirconium, lanthanum, and thorium. Comprehensive characterisation confirmed a 1:1:1 metal-to-ligand ratio, with dithranol coordinating through two hydroxyl oxygen atoms and a carbonyl group, and glycine binding via a carboxylic oxygen and nitrogen. Except for the zirconium complex, the compounds exhibited nanocrystalline structures with crystallite sizes between 35.50 and 55.57 nanometres. Cytotoxic evaluations on the aggressive 66cl-4 breast cancer cell line revealed marked antiproliferative effects. The thorium(IV) complex demonstrated the strongest activity, achieving an IC50 of 9.39 micromolar. It also suppressed the expression of matrix metalloproteinase-9, a key protein involved in tumour metastasis, by 86 percent at a concentration of 25 micromolar, with molecular docking simulations supporting its binding behaviour.

Key takeaways

  • Five mixed-ligand complexes of dithranol and glycine were synthesised with nickel, zinc, zirconium, lanthanum, and thorium.
  • Most of the complexes formed nanocrystalline structures with crystallite sizes ranging from 35.50 to 55.57 nanometres.
  • The thorium(IV) complex showed the highest potency against aggressive 66cl-4 breast cancer cells with an IC50 of 9.39 micromolar.
  • At 25 micromolar, the thorium(IV) complex reduced expression of the metastasis-linked protein matrix metalloproteinase-9 by 86 percent.

Why it matters

Aggressive breast cancers often metastasise, making effective treatment difficult and highlighting the need for novel therapeutic agents. Matrix metalloproteinase-9 is an enzyme that facilitates cancer spread. Demonstrating that metal-based drug candidates can directly suppress this enzyme while killing aggressive cancer cells offers promising biochemical leads for tackling hard-to-treat malignancies.

Commercialisation angle

This research is at an early experimental stage within medicinal chemistry. The findings could interest oncology drug discovery teams and pharmaceutical developers seeking new coordination complexes as therapeutic leads against metastatic breast cancer. Significant development hurdles remain, including extensive in vitro selectivity screens, in vivo safety and efficacy validation, and pharmacokinetic studies, placing any commercial application several years away.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

Five novel complexes of nickel (II)( 1 ), zinc (II)( 2 ), zirconium (IV)( 3 ), lanthanum (III)( 4 ), thorium (IV)( 5 ), with the dithranol ( Dithr ) ligand and glycine ( Gly ) were synthesized and characterized. Their structures were investigated using elemental analysis, molar conductance (Λ), magnetic studies ( μ eff ), spectroscopic methods (FT‐IR, UV–Vis., 1 H NMR, XRD), mass spectrometry, TG/DTG and DTA. Findings revealed that Dithr was chelated via two hydroxyl oxygen atoms and carbonyl group while, Gly chelated through carboxylic oxygen and nitrogen atom. All complexes appeared with molar ratio 1:1:1 ( M : Dithr : Gly ) and were electrolytes with 1:1 for ( 1 ), ( 2 ) and ( 3 ) complexes, 1:2 for ( 4 ) complex, and 1:3 for ( 5 ) complex according to elemental analysis and molar conductivity data. All metal‐chelates, except Th (IV)‐complex, were confirmed to have lattice water molecules based on their thermal behavior. Average crystalline size of all compounds was calculated using XRD analysis and found in the range 35.50–55.57 nm, indicating the compounds existed as nanocrystalline structure, except zirconium (IV) complex. Then, we studied cytotoxic effects of our synthetic drugs on the survival of an aggressive‐breast‐cancer‐histotype“66cl‐4.” Given its involvement in cancer‐metastasis, matrix‐metalloproteinase‐(MMP)‐9 protein expression was evaluated using western‐blotting‐assays. Th(IV)‐complex emerged as the most effective option in inhibiting cancer‐cells‐proliferation (IC 50 : 9.39 μM), and suppressed expression MMP‐9 levels by 86%, at 25 μM dose, and drug‐binding‐affinity was interpreted via molecular modeling.

Research topics

  • Metal complexes synthesis and properties
  • Computational Drug Discovery Methods
  • Organometallic Compounds Synthesis and Characterization

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1002/aoc.7650

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.